Seattle, WA (PRWEB) July 31, 2015
BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in Seattle, WA is rapidly transforming the way we treat aging diseases.
BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising gene therapy to treat patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the money raised to BioViva to help bring pioneering gene therapy to cure this disease and make AD a thing of the past.
Despite years of research and billions of dollars, there is still no cure for AD, and there are multiple negative side effects of approved medications. Many current approaches focus on consequences alone, but BioViva’s gene therapy could offer a cure.
Improvements of AD symptoms and the recovery of normal brain functions have been demonstrated in-vivo in mouse experiments, and in-vitro in human cell experiments through the rejuvenation of microglia (the brain’s first line of defense against infection) and neurons and stimulating mitochondrial function using the telomerase reverse transcriptase (TERT) protein.
In recent studies, Alzheimer’s symptoms were found in brain images in people as young as 20. By the time of diagnosis, up to 40% of the brain can be damaged. “If we can prove a benefit to patients that have no other option now, we can potentially treat Alzheimer’s Disease in people before these symptoms arise, creating real preventative medicine at the cellular level,” states BioViva’s CEO Elizabeth Parrish. “If successful this treatment could potentially be used on other neurodegenerative diseases.”
BioViva is developing labs and partner clinics worldwide. With a world class Scientific Advisory Board including George Church, a professor of Genetics at Harvard Medical School; George Martin, Director Emeritus of the Alzheimer’s Disease Research Center, University of Washington; and the recent addition of Avi Roy an Oxford based Biogerontologist as Chief Scientific Officer, we are ready to push forward into practical solutions. BioViva has the mandate of the scientific community to move forward and treat diseases with no previous cure.
BioViva’s unique difference is treating the cellular degeneration caused by aging as the root cause of most major diseases. Studies have proven aging is the leading risk factor for many life threatening diseases including Alzheimer's.
“This technology has the ability to reverse the age related dysfunction in cells and tissues and the damage it causes. It could halt many of the big age associated killers in industrialized countries’” states Parrish. Compassionate care helps patients with no other option get access to experimental therapies that may benefit both themselves and society as a whole.
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.
BioViva USA, Inc.
Maximum Life Foundation